BidaskClub downgraded shares of Five Prime Therapeutics (NASDAQ:FPRX) from a hold rating to a sell rating in a research report report published on Thursday.
Several other research analysts have also weighed in on the stock. Zacks Investment Research lowered shares of Five Prime Therapeutics from a buy rating to a hold rating in a research note on Thursday, November 9th. ValuEngine lowered shares of Five Prime Therapeutics from a hold rating to a sell rating in a research note on Tuesday, November 7th. BMO Capital Markets increased their target price on shares of Five Prime Therapeutics from $71.00 to $75.00 and gave the stock an outperform rating in a research note on Tuesday, November 7th. Finally, Royal Bank of Canada increased their target price on shares of Five Prime Therapeutics from $41.00 to $50.00 and gave the stock an outperform rating in a research note on Monday, November 6th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the stock. Five Prime Therapeutics currently has an average rating of Hold and an average target price of $64.00.
Shares of Five Prime Therapeutics (NASDAQ FPRX) traded up $0.14 during mid-day trading on Thursday, reaching $21.96. 234,024 shares of the company’s stock traded hands, compared to its average volume of 326,932. The stock has a market capitalization of $635.30, a price-to-earnings ratio of -4.34 and a beta of 3.91. Five Prime Therapeutics has a one year low of $19.73 and a one year high of $49.30.
In other news, Director William R. Ringo sold 600 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $45.33, for a total value of $27,198.00. Following the completion of the transaction, the director now owns 600 shares of the company’s stock, valued at $27,198. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 6.50% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Oppenheimer & Co. Inc. purchased a new position in shares of Five Prime Therapeutics in the third quarter valued at approximately $223,000. Dupont Capital Management Corp purchased a new position in shares of Five Prime Therapeutics in the third quarter valued at approximately $341,000. Legal & General Group Plc boosted its stake in shares of Five Prime Therapeutics by 3.1% in the second quarter. Legal & General Group Plc now owns 9,455 shares of the biotechnology company’s stock valued at $288,000 after purchasing an additional 287 shares during the period. Virtu KCG Holdings LLC purchased a new position in shares of Five Prime Therapeutics in the second quarter valued at approximately $331,000. Finally, Tudor Investment Corp ET AL boosted its stake in shares of Five Prime Therapeutics by 49.4% in the second quarter. Tudor Investment Corp ET AL now owns 11,999 shares of the biotechnology company’s stock valued at $361,000 after purchasing an additional 3,966 shares during the period. 83.66% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “Five Prime Therapeutics (FPRX) Rating Lowered to Sell at BidaskClub” was originally reported by Ticker Report and is owned by of Ticker Report. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3149126/five-prime-therapeutics-fprx-rating-lowered-to-sell-at-bidaskclub.html.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.